DXRX
NEUTRALDiaceutics PLC Provides General Update
The diagnostic commercialization company provides a general update on its operations.
Diaceutics
143.50GBX
0.35%
Market Cap
121.32M
Volume
161.49k
102% of avg
P/E Ratio
72.11
EPS (TTM)
1.99
Beta
0.75
Day Range
142.00p - 148.00p
52 Week Range
106.00p143.50p151.00p
143.50p
Upcoming Events
DXRX
NEUTRALDiaceutics PLC Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
DXRX
NEUTRALDiaceutics Announces PDMR Shareholding and Share Incentive Plan
The diagnostic commercialization company provides an update on PDMR shareholding and its share incentive plan.
DXRX
NEUTRALDiaceutics PLC Announces Major Shareholding Change
The healthcare information services company has reported a change in major shareholding, with Gresham House Asset Management Ltd now holding 16.29% of the voting rights.
DXRX
NEUTRALDiaceutics to Present at Canaccord Genuity Growth Conference
The healthcare technology company will present at an upcoming investor conference.
DXRX
NEUTRALDiaceutics Appoints New General Counsel and Company Secretary
The healthcare technology company has appointed a new Executive Vice President, Legal, General Counsel, and Group Company Secretary.
DXRX
NEUTRALDiaceutics PLC Announces Change in Shareholding
The healthcare services provider has announced a change in its major shareholding.
DXRX
NEUTRALDiaceutics PLC Issues Share Options to Management Team
The healthcare technology company has granted share options to its management team as part of its long-term incentive plan.
DXRX
VERY GOODDiaceutics Reports 22% Revenue Growth in H1 2025
The diagnostic commercialization company reported 22% revenue growth in H1 2025, driven by strong commercial momentum and expanding customer adoption of its solutions.
DXRX
GOODDiaceutics Expands PMx Commercialization Partnership
The diagnostic commercialization company has expanded its PMx partnership, introducing a new service and expecting incremental revenue in the coming year.